Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 1/20 | 0.66 |
| ▸ | CDK4 | P11802 | 1/20 | 0.66 |
| ▸ | CDK2 | P24941 | 1/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | PNP | P00491 | 1/20 | 0.41 |
| ▸ | CASP6 | P55212 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13513904 | 0.79 | NPSR1 (0.46) | CDK1CDK4CDK2KDM4EMEN1 | |
| SCHEMBL28538636 | 0.79 | CDK1 (1.00) | CDK1CDK4CDK2KDM4EMEN1 | |
| SCHEMBL14080318 | 0.77 | CDK1 (0.43) | CDK1CDK4CDK2KDM4EMEN1 | |
| SCHEMBL4572376 | 0.76 | CDK1 (0.66) | CDK1CDK4CDK2KDM4EMEN1 | |
| SCHEMBL13833302 | 0.76 | CDK1 (0.66) | CDK1CDK4CDK2KDM4EMEN1 | |
| SCHEMBL12820920 | 0.76 | KDM4E (0.60) | CDK1CDK4CDK2KDM4EMEN1 | |
| SCHEMBL25057438 | 0.75 | NPSR1 (0.46) | CDK1CDK4CDK2KDM4EMEN1 | |
| SCHEMBL18519949 | 0.75 | NPSR1 (0.43) | CDK1CDK4CDK2KDM4EMEN1 | |
| SCHEMBL18519988 | 0.74 | NPSR1 (0.45) | CDK1CDK4CDK2KDM4EMEN1 | |
| SCHEMBL718210 | 0.74 | NPSR1 (0.52) | CDK1CDK4CDK2MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110124634-A1 | BIOACTIVE COMPOUNDS FOR TREATMENT OF CANCER AND NEURODEGENERATIVE DISEASES | PONIARD PHARMACEUTICALS, INC. | 2011-05-26 | — | — | US | disclosed |
| US-20100279974-A1 | Nucleosides With Non-Natural Bases as Anti-Viral Agents | IDENIX PHARMACEUTICALS, INC. | 2010-11-04 | — | — | US | disclosed |
| US-7405297-B2 | Process for preparing inhibitors of nucleoside metabolism | INDUSTRIAL RESEARCH LIMITED (NZ) | 2008-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124634-A1 | BIOACTIVE COMPOUNDS FOR TREATMENT OF CANCER AND NEURODEGENERATIVE DISEASES | PARK7, BDNF, BACE1 | CDK1 232/4885CDK4 593/4885CDK2 677/4885 |
| US-20100279974-A1 | Nucleosides With Non-Natural Bases as Anti-Viral Agents | PNP, NSUN2, NME2 | CDK1 3033/4885CDK4 4066/4885CDK2 3421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.